HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

5-methoxy-1H-2-indolylphenylmethanone

structure in first source

Also Known As:

5-methoxy-1H-2-indolyl-phenylmethanone; D-64131; D64131

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - 5-methoxy-1H-2-indolylphenylmethanone: 1

Experts

1.	Beckers, Thomas: 1 article (06/2002)
2.	Burger, Angelika M: 1 article (06/2002)
3.	Fiebig, Heinz H: 1 article (06/2002)
4.	Frieser, Markus: 1 article (06/2002)
5.	Hockemeyer, Jörg: 1 article (06/2002)
6.	Hufsky, Harald: 1 article (06/2002)
7.	Mahboobi, Siavosh: 1 article (06/2002)
8.	Pongratz, Herwig: 1 article (06/2002)
9.	Reissmann, Thomas: 1 article (06/2002)
10.	Schmidt, Mathias: 1 article (06/2002)

Related Diseases

1.	Neoplasms (Cancer) 06/01/2002 - "In xenograft experiments with the human amelanoic melanoma MEXF 989, D-64131 was highly active with treatment resulting in a growth delay of 23.4 days at 400 mg/kg. Therefore, D-64131 and analogues have the potential to be developed for cancer therapy, replacing or supplementing standard therapy regimens with tubulin-targeting drugs from natural sources." 06/01/2002 - "The proliferation of tumor cells from 12 of 14 different organs and tissues was inhibited with mean IC(50)s of 62 nM and 24 nM by D-64131 and D-68144, respectively, comparable with the potency of paclitaxel with mean IC(50) of 10 nM. By measuring the cytotoxicity in a human colon carcinoma cell model with ectopic ecdysone-inducible expression of the cyclin-dependent kinase inhibitor p21(WAF1), specificity toward cycling cells was demonstrated. "
2.	Melanoma (Melanoma, Malignant) 06/01/2002 - "In xenograft experiments with the human amelanoic melanoma MEXF 989, D-64131 was highly active with treatment resulting in a growth delay of 23.4 days at 400 mg/kg. Therefore, D-64131 and analogues have the potential to be developed for cancer therapy, replacing or supplementing standard therapy regimens with tubulin-targeting drugs from natural sources."
3.	Carcinoma (Carcinomatosis) 06/01/2002 - "The proliferation of tumor cells from 12 of 14 different organs and tissues was inhibited with mean IC(50)s of 62 nM and 24 nM by D-64131 and D-68144, respectively, comparable with the potency of paclitaxel with mean IC(50) of 10 nM. By measuring the cytotoxicity in a human colon carcinoma cell model with ectopic ecdysone-inducible expression of the cyclin-dependent kinase inhibitor p21(WAF1), specificity toward cycling cells was demonstrated. "

Related Drugs and Biologics

1.	Cyclin-Dependent Kinase Inhibitor p21
2.	Paclitaxel (Taxol)
3.	Tubulin
4.	Ecdysone

Related Therapies and Procedures

1.	Therapeutics